GENCURIX
GenesWell - Model BCT - Multigene Prognostic Test Kit for Early Breast Cancer
FromGENCURIX
Multigene prognostic test predicts the probability of metastasis or recurrence, which helps patients make treatment decision. It improves quality of life for cancer patients as preventing them from unnecessary chemotherapy.
Most popular related searches
breast cancer
breast cancer risk
tumor tissue
cancer patient
cancerous breast
metastasis
cancer risk
chemotherapy
cancer prevention
cancer early
GenesWell BCT predicts probability of distant metastasis and chemobenefit within 10 years after surg
Process
- Extract RNA from tumor tissue
- Analyze expression level of prognostic genes related in breast cancer
- Calculate risk using GenesWell BCT Algorithm
- Provide results of risk classification and probability of distant metastasis